Cell Therapeutics’ Adaptive Trial Interim Data May Allow For 2007 Lymphoma NDA

Company says Phase III interim results of pixantrone adaptive trial are “highly significant” and could lead to an NDA submission for relapsed, aggressive non-Hodgkin’s lymphoma.